LIGAND PHARMACEUTICAL INC (LGNXZ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 47.23 Million USD | -16.0% |
| 2022 | 56.23 Million USD | -47.73% |
| 2021 | 133.16 Million USD | 193.18% |
| 2020 | 44.84 Million USD | -3.45% |
| 2019 | 876.11 Million USD | -78.93% |
| 2018 | 238.29 Million USD | 123.86% |
| 2017 | 81.15 Million USD | 43.39% |
| 2016 | 31.42 Million USD | 81.45% |
| 2015 | 49.75 Million USD | 57.83% |
| 2014 | 18.81 Million USD | 31.34% |
| 2013 | 13.94 Million USD | 2503.31% |
| 2012 | 574 Thousand USD | 182.23% |
| 2011 | -698 Thousand USD | 97.62% |
| 2010 | -13.13 Million USD | -194.01% |
| 2009 | -9.96 Million USD | 89.75% |
| 2008 | -97.27 Million USD | -61.66% |
| 2007 | -50.1 Million USD | 64.34% |
| 2006 | -168.77 Million USD | -537.57% |
| 2005 | -26.47 Million USD | 64.24% |
| 2004 | -18.26 Million USD | -285.95% |
| 2003 | -19.17 Million USD | 20.59% |
| 2002 | -24.15 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 16.74 Million USD | -547.76% |
| 2024 Q1 | 12.23 Million USD | -54.12% |
| 2023 Q1 | 23.77 Million USD | 337.22% |
| 2023 Q3 | 9.83 Million USD | 30.64% |
| 2023 Q2 | 7.52 Million USD | -68.34% |
| 2023 Q4 | 6.07 Million USD | -38.25% |
| 2023 FY | - USD | -16.0% |
| 2022 Q2 | 12.61 Million USD | 190.87% |
| 2022 Q3 | 14.14 Million USD | 12.07% |
| 2022 Q1 | 4.33 Million USD | -83.11% |
| 2022 FY | - USD | -47.73% |
| 2022 Q4 | -10.02 Million USD | -170.86% |
| 2021 Q1 | 17.8 Million USD | -44.33% |
| 2021 Q3 | 24.51 Million USD | 2.46% |
| 2021 Q2 | 23.93 Million USD | 34.38% |
| 2021 Q4 | 25.68 Million USD | 4.74% |
| 2021 FY | - USD | 193.18% |
| 2020 Q2 | 7.1 Million USD | 87.43% |
| 2020 FY | - USD | -3.45% |
| 2020 Q3 | 3.74 Million USD | -47.23% |
| 2020 Q4 | 31.98 Million USD | 753.7% |
| 2020 Q1 | 3.78 Million USD | 0.0% |
| 2019 Q2 | -4.13 Million USD | -100.5% |
| 2019 FY | - USD | -78.93% |
| 2019 Q1 | 826.54 Million USD | 0.0% |
| 2019 Q3 | -5.15 Million USD | -24.89% |
| 2018 Q3 | 23.36 Million USD | -66.71% |
| 2018 Q2 | 70.17 Million USD | 89.45% |
| 2018 FY | - USD | 123.86% |
| 2018 Q1 | 37.04 Million USD | 0.0% |
| 2017 Q2 | 13.01 Million USD | 27.4% |
| 2017 FY | - USD | 43.39% |
| 2017 Q3 | 16.49 Million USD | 26.72% |
| 2017 Q1 | 10.21 Million USD | 0.0% |
| 2016 Q2 | 4.36 Million USD | -71.09% |
| 2016 Q1 | 15.09 Million USD | 0.0% |
| 2016 Q3 | 5.46 Million USD | 25.22% |
| 2016 FY | - USD | 81.45% |
| 2015 FY | - USD | 57.83% |
| 2015 Q3 | 8.59 Million USD | 96.95% |
| 2015 Q2 | 4.36 Million USD | 30.34% |
| 2015 Q1 | 3.34 Million USD | 0.0% |
| 2014 Q3 | 3.53 Million USD | 160.09% |
| 2014 FY | - USD | 31.34% |
| 2014 Q1 | 5.1 Million USD | 0.0% |
| 2014 Q2 | 1.35 Million USD | -73.37% |
| 2013 Q3 | 3.07 Million USD | 102.77% |
| 2013 Q2 | 1.51 Million USD | -61.5% |
| 2013 Q1 | 3.93 Million USD | 0.0% |
| 2013 FY | - USD | 2503.31% |
| 2012 FY | - USD | 182.23% |
| 2012 Q2 | -1.73 Million USD | -126.14% |
| 2012 Q3 | -1.32 Million USD | 23.58% |
| 2012 Q1 | -765 Thousand USD | 0.0% |
| 2011 Q1 | -1.48 Million USD | 0.0% |
| 2011 Q2 | -810 Thousand USD | 45.38% |
| 2011 FY | - USD | 97.62% |
| 2011 Q3 | -3.24 Million USD | -301.11% |
| 2010 FY | - USD | -194.01% |
| 2010 Q3 | -15.67 Million USD | -332.06% |
| 2010 Q2 | -3.62 Million USD | 9.89% |
| 2010 Q1 | -4.02 Million USD | 0.0% |
| 2009 Q1 | -7.31 Million USD | 0.0% |
| 2009 FY | - USD | 89.75% |
| 2009 Q2 | -4.65 Million USD | 36.36% |
| 2009 Q3 | 774 Thousand USD | 116.62% |
| 2008 Q3 | -6.35 Million USD | -12.82% |
| 2008 Q2 | -5.63 Million USD | 52.66% |
| 2008 Q1 | -11.89 Million USD | 0.0% |
| 2008 FY | - USD | -61.66% |
| 2007 FY | - USD | 64.34% |
| 2007 Q1 | -29.04 Million USD | 0.0% |
| 2007 Q2 | -14.36 Million USD | 50.54% |
| 2007 Q3 | -8.72 Million USD | 39.27% |
| 2006 Q1 | -137.1 Million USD | 0.0% |
| 2006 Q2 | -10.99 Million USD | 91.98% |
| 2006 Q3 | -15.06 Million USD | -37.08% |
| 2006 FY | - USD | -537.57% |
| 2005 FY | - USD | 64.24% |
| 2005 Q2 | -6.5 Million USD | 58.74% |
| 2005 Q1 | -15.77 Million USD | 0.0% |
| 2005 Q3 | -3.51 Million USD | 45.98% |
| 2004 FY | - USD | -285.95% |
| 2004 Q1 | -10.26 Million USD | 0.0% |
| 2004 Q2 | -11.26 Million USD | -9.73% |
| 2003 FY | - USD | 20.59% |
| 2003 Q2 | -9.07 Million USD | 27.8% |
| 2003 Q1 | -12.56 Million USD | 0.0% |
| 2003 Q3 | -8.19 Million USD | 9.66% |
| 2002 Q3 | -6.78 Million USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alternative Energy Partners, Inc. | -251.11 USD | 18809386.767% |
| Allstar Health Brands, Inc. | -241.78 Thousand USD | 19634.549% |
| Beijing Tong Ren Tang Chinese Medicine Company Limited | 89.4 Million USD | 47.168% |
| Café Serendipity Holdings, Inc. | -1.41 Million USD | 3437.252% |
| Decision Diagnostics Corp. | - USD | -Infinity% |
| Health Advance Inc. | -47.95 Thousand USD | 98586.175% |
| HealthWarehouse.com, Inc. | -1.27 Million USD | 3803.579% |
| MedGen, Inc. | -15.37 USD | 307300034.938% |
| Omni Health, Inc. | 1.28 Million USD | -3568.226% |
| Oxford Investments Holdings Inc. | -343.96 Thousand USD | 13831.59% |
| Pineapple, Inc. | -1.47 Million USD | 3301.566% |
| ScripsAmerica, Inc. | -3.95 Million USD | 1294.396% |